PRRT2 and Duchenne muscular dystrophy: Our findings make PKCθ a very attractive target to counteract Duchenne Muscular Dystrophy and provide proof of principle that its pharmacological inhibition in DMD can be proposed in order to counteract the disease, as long as specific and selective PKCθ inhibitors, with a defined therapeutic profile will be characterized.